香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 Shandong Boan Biotechnology Co., Ltd. 竇 博 士 已 確 認 其 本 人 與 董 事 會 並 無 任 何 意 見 分 歧，亦 無 任 何 與 其 辭 任 有 關 之 事 項 須 提 呈 香 港 聯 合 交 易 所 有 限 公 司 及 本 公 司 股 東 垂 注。 竇 博 士 任 職 期 間，恪 盡 職 守、勤 勉 盡 責，為 本 公 司 的 持 續 增 長 及 發 展 作 出 了 積 極 貢 獻，董 事 會 對 竇 博 士 任 職 期 間 的 辛 勤 付 出 表 示 由 衷 感 謝。 – 1 – 董事會委員會組成變動 （股 份 代 號：6955） (1)執 行 董 事 辭 任；及 (2)董事會委員會組成變動 執行董事辭任 山東博安生物技術股 份有限公司（「本公司」，連 同 其 附 屬 公 司 統 稱「本集團」） ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 對 因 本 公 告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 執行董事 非執行董事 姜華女士 劉元沖先生 王盛翰先生 李莉女士 李世旭先生 獨立非執行董事 史錄文先生 戴繼雄先生 余家林博士 董 事 會 設 立 五 個 委 員 會。下 表 提 供 各 董 事 會 成 員 於 該 等 委 員 會 中 所 擔 任 的 職 位。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 董事名單及其角色和職能 山東博安生物技術股份 有限公司董事會（「董事會」）成 員 如 下： | | 董 事 | 審 計 | 薪 酬 | 提 名 | 戰 略 | 環 境、 社會及 | | --- | --- | --- | --- | --- | --- | --- | | 董 ...

Financial Performance - For the fiscal year ending December 31, 2025, the company's revenue was approximately RMB 784.8 million, an increase of about RMB 58.5 million or 8.1% compared to RMB 726.3 million for the fiscal year ending December 31, 2024[3]. - The gross profit for the fiscal year ending December 31, 2025, was approximately RMB 562.4 million, an increase of about RMB 19.7 million or 3.6% compared to RMB 542.7 million for the fiscal year ending December 31, 2024[5]. - The company reported a profit before tax of RMB 7.1 million for the fiscal year ending December 31, 2025, a significant decrease from RMB 73.2 million for the fiscal year ending December 31, 2024[8]. - The total comprehensive income for the fiscal year ending December 31, 2025, was RMB 6.9 million, down from RMB 73.1 million for the fiscal year ending December 31, 2024[8]. - The net profit for the year ended December 31, 2025, was RMB 7.1 million, a significant decrease from RMB 73.2 million for the year ended December 31, 2024[125]. - Other income and gains totaled approximately RMB 15.5 million for the year ended December 31, 2025, a significant decrease from RMB 45.1 million in 2024[118]. Cost and Expenses - The cost of sales increased from RMB 183.7 million for the fiscal year ending December 31, 2024, to approximately RMB 222.4 million for the fiscal year ending December 31, 2025, representing about 28.3% of total revenue for the same year (2024: 25.3%) [4]. - Sales and distribution expenses rose to RMB 340.9 million for the fiscal year ending December 31, 2025, up from RMB 285.8 million for the fiscal year ending December 31, 2024, marking a 19.3% increase[6]. - Research and development expenses for the fiscal year ending December 31, 2025, were approximately RMB 147.6 million, a decrease of about RMB 1.7 million compared to RMB 149.3 million for the fiscal year ending December 31, 2024[7]. - Financial costs totaled RMB 38,658 thousand in 2025, up from RMB 32,651 thousand in 2024, marking an increase of 18.4%[30]. - Administrative expenses decreased from RMB 46.5 million for the year ended December 31, 2024, to RMB 41.2 million for the year ended December 31, 2025, due to improved management measures[120]. Assets and Liabilities - Non-current assets increased to RMB 2,112,330 thousand in 2025 from RMB 1,895,008 thousand in 2024, representing an increase of approximately 11.5%[9]. - Current assets rose significantly to RMB 2,013,310 thousand in 2025, up from RMB 956,280 thousand in 2024, marking an increase of approximately 110.9%[9]. - Total liabilities decreased to RMB 1,385,753 thousand in 2025 from RMB 1,297,250 thousand in 2024, a reduction of about 6.8%[10]. - Net assets increased to RMB 2,739,887 thousand in 2025, compared to RMB 1,644,038 thousand in 2024, reflecting a growth of approximately 66.6%[10]. - The company reported cash and cash equivalents of RMB 1,130,402 thousand in 2025, a significant increase from RMB 198,867 thousand in 2024, representing a growth of approximately 468.5%[9]. Market and Product Development - The company has commercialized five products during the reporting period, contributing to rapid revenue growth[3]. - The company has established a professional commercialization team to strengthen its market position domestically, laying a solid foundation for future transformation[3]. - The company has five approved products and is developing biopharmaceutical products in markets including the USA, EU, UK, and Japan[58]. - The company focuses on multiple therapeutic areas including oncology, autoimmune diseases, ophthalmology, and metabolic diseases[57]. - The company has a balanced product pipeline with five approved products and eight candidates in various clinical trial stages, focusing on oncology, metabolism, autoimmune, and ophthalmology[65]. Research and Development - The company continues to strengthen its R&D capabilities with a team of 245 experienced employees across various research functions[61]. - The company has a proprietary R&D platform focused on antibody discovery and drug development, with facilities in Yantai, Nanjing, and Boston[93]. - The company has filed multiple patent applications globally, with 53 patents granted and 43 pending as of the announcement date[96]. - The company has established strong CMC capabilities, ensuring high quality and cost efficiency throughout the drug development and commercialization process[94]. Strategic Partnerships and Collaborations - The company has entered into a strategic partnership with DeepMind Technology to build an AI-driven innovation model as of March 2026[63]. - The company is actively discussing licensing or co-development of its innovative drug pipeline with several pharmaceutical companies and investment institutions[106]. - The company is collaborating with various well-resourced business partners to enhance its market presence and product accessibility[104]. Corporate Governance - The revised corporate governance code will take effect on July 1, 2025, and will apply to the company's corporate governance report and annual report for fiscal years starting on or after this date[144]. - The company has established appropriate checks and balances regarding the dual role of the Chairman and CEO, held by Ms. Jiang Hua, who has extensive experience in the pharmaceutical industry[145]. - The company has adopted a set of conduct rules for directors regarding securities trading, which meet or exceed the standards set forth in the listing rules[146].

山東博安生物技術股 份有限公司（「本公司」）董事會（「董事會」）謹 此 宣 佈，本 公 司將於二零二六年三月三十日（星 期 一）舉 行 董 事 會 會 議，藉 以（其 中 包 括）批 准 本 公 司 截 至 二 零 二 五 年 十 二 月 三 十 一 日 止 之 年 度 業 績 及 其 發 佈，並 考 慮 派 發 末期股息（如 有）。 承董事會命 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示 概 不 就 因 本 公 告 全 部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Shandong Boan Biotechnology Co., Ltd. 山東博安生物技術股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：6955） 董事會會議通告 山東博安生物技術 股份有限公司 主 席、首 席 執 行 官 及 執 行 董 事 姜 華 中 華 人 民 共 和 國，煙 台，二 零 二 六 年 三 月 十 七 日 於 本 公 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 備註： 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，在上述「法定/註冊股本」部分顯示的資料是指本公司的註冊股本 FF301 第 1 頁 共 10 頁 v 1.2.0 公司名稱: 山東博安生物技術股份有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06955 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 622,333,694 | RMB | | 1 | RMB | | 622,333,694 | | 增加 / 減少 (-) ...

Group 1 - The innovative drug industry is showing signs of recovery, with factors such as increased investment and financing, record overseas expansion, and improved review efficiency potentially impacting biotechnology companies like Boan Biologics [1] Group 2 - Boan Biologics' stock price has fluctuated recently, with a range of 0.65% and a volatility of 6.06%. On February 10, the stock rose by 2.09% to 8.05 HKD, with a trading volume of 310 million HKD; on February 11, it closed flat at 7.80 HKD with reduced trading volume [2] Group 3 - Some institutions have set a target average price of 10.44 HKD for the company based on its innovative drug pipeline, indicating potential upside from the current price, but caution is advised due to uncertainties in profit forecasts [3]

截至月份: 2026年1月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06955 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 622,333,694 | RMB | | 1 RMB | | 622,333,694 | 本月底法定/註冊股本總額： RMB 622,333,694 備註： 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概 ...

Group 1 - The core point of the article highlights that on February 2, Boan Biotechnology (06955) shareholders transferred stocks from CITIC Securities Brokerage Hong Kong to HSBC Hong Kong, with a transfer market value of HKD 848 million, accounting for 16.37% of the total [1] - Boan Biotechnology's board has been informed by its controlling shareholder, Green Leaf Pharmaceutical Group, regarding a proposed transfer of 11.9866 million H-shares by its wholly-owned subsidiary, Shandong Green Leaf Pharmaceutical Co., Ltd., to be executed in the market by January 27, 2026, as per the terms of the subscription agreement related to the exchangeable preferred shares [1]

Group 1 - The core point of the article highlights that on February 2, Boan Biotechnology (06955) transferred shares from CITIC Securities Brokerage Hong Kong to HSBC Hong Kong, with a market value of HKD 848 million, accounting for 16.37% of the total shares [1] - The company announced that its board has been informed by its controlling shareholder, Green Leaf Pharmaceutical Group, regarding a proposed transfer of 11.9866 million H-shares by its wholly-owned subsidiary, Shandong Green Leaf Pharmaceutical Co., Ltd., scheduled for January 27, 2026 [1]

Core Viewpoint - The stock price of Bohan Biotech (06955) has experienced a significant decline since reaching a peak of HKD 19.90 on August 8 last year, with a low of HKD 8.15 on January 5 this year, marking a volatility of 59.05% [1]. Group 1: Stock Performance and Market Sentiment - Since August 8, Bohan Biotech has been in a downward trend characterized by "price drop and volume shrinkage," with the stock price fluctuating between the Bollinger Bands' middle and lower bands [2]. - The stock attempted a rebound after touching the lower Bollinger Band on August 20, but failed due to a lack of trading volume and market enthusiasm [2]. - A significant bullish candle on September 16 saw a 12% increase in stock price, but did not improve overall market sentiment, leading to continued downward pressure [4]. - The stock price showed signs of a potential rebound after touching the lower Bollinger Band for the sixth time on January 2, with a notable increase in trading volume on January 9 [5]. Group 2: Financial Performance and Market Position - Bohan Biotech's market capitalization was HKD 53.12 billion at the end of last year, but the current stock price is below HKD 60 billion, which is necessary to maintain its position in the Hong Kong Stock Connect [1]. - The company reported a revenue of HKD 393 million for the first half of 2025, a year-on-year increase of 8.39%, but net profit fell by 66.74% due to a high base from the previous year [7]. - Despite the decline in net profit, the company maintained a gross margin of 71.83% and a significant increase in cash flow, with cash and cash equivalents reaching HKD 660 million, up 231.86% year-on-year [7]. Group 3: Future Prospects and Pipeline - The upcoming review period for the Hong Kong Stock Connect is set for September 7, with the average market capitalization requirement being HKD 66.74 billion, only slightly below the current market cap of HKD 69.14 billion [6]. - Bohan Biotech has promising research pipelines, including a PD-1/IL-2 antibody fusion protein PR201, which is expected to submit an IND application in Q2 2026, and PR203, a dual-target antibody with potential for significant business development opportunities [8].